NCT04756401View on ClinicalTrials.gov

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 30, 2027

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Carfilzomib

Given IV

BIOLOGICAL

Daratumumab

Given IV

DRUG

Dexamethasone

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Selinexor

Given PO

Trial Locations (4)

13210

State University of New York Upstate Medical University, Syracuse

27599

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill, Chapel Hill

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER